Please ensure Javascript is enabled for purposes of website accessibility
WHO Study Finds Remdesivir Didn't Help COVID-19 Patients
gvw_ap_news
By Associated Press
Published 5 years ago on
October 16, 2020

Share

GENEVA — A large study led by the World Health Organization suggests that the antiviral drug remdesivir did not help hospitalized COVID-19 patients, in contrast to an earlier study that made the medicine a standard of care in the United States and many other countries.

The results announced Friday do not negate the previous ones, and the WHO study was not as rigorous as the earlier one led by the U.S. National Institutes of Health. But they add to concerns about how much value the pricey drug gives because none of the studies have found it can improve survival.

The drug has not been approved for COVID-19 in the U.S., but it was authorized for emergency use after the previous study found it shortened recovery time by five days on average. It’s approved for use against COVID-19 in the United Kingdom and Europe, and is among the treatments U.S. President Donald Trump received when he was infected earlier this month.

The WHO study involved more than 11,000 patients in 30 countries. About 2,750 were randomly assigned to get remdesivir. The rest got either the malaria drug hydroxychloroquine, the immune-system booster interferon, the antiviral combo lopinavir-ritonavir, or just usual care. The other drugs have largely been ruled out for COVID-19 by previous studies, but not remdesivir.

“In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP)”

The Results Have Not Been Published in a Journal or Reviewed by Independent Scientists

Death rates after 28 days, the need for breathing machines and time in the hospital were relatively similar for those given remdesivir versus usual care.

The results have not been published in a journal or reviewed by independent scientists, but were posted on a site researchers use to share results quickly.

“The big story is the finding that remdesivir produces no meaningful impact on survival,” Martin Landray, an Oxford University professor who led other coronavirus treatment research, said in a statement.

“This is a drug that has to be given by intravenous infusion for five to 10 days,” and costs about $2,550 per treatment course, he said. “COVID affects millions of people and their families around the world. We need scalable, affordable and equitable treatments.”

Dr. Margaret Harris, a WHO spokeswoman, attributed the difference in the conclusions of the two studies to the fact WHO’s was larger.

“It’s just a much higher-powered study,” she said. “It’s quadruple the number of people in all the other studies.”

Results Are Inconsistent With More Rigorous Studies and Have Not Been Fully Reviewed or Published

However, Dr. Andre Kalil, a University of Nebraska infectious disease specialist who helped lead the U.S. remdesivir study, said the WHO one was poorly designed, which makes its conclusions less reliable. Patients and doctors knew what treatment they were using, there was no placebo infusion to help avoid biased reporting of risks or benefits, there was little information about the severity of patients’ symptoms when treatments began and a lot of missing data, he said.

“Poor quality study design cannot be fixed by a large sample size, no matter how large it is,” Kalil wrote in an email.

Furthermore, the WHO study tested 10 days of remdesivir, so some patients may have been hospitalized longer than they needed to be just to finish treatment, making their length of stay look bad in comparison to others getting usual care.

Remdesivir’s maker, Gilead Sciences, said in a statement that the results are inconsistent with more rigorous studies and have not been fully reviewed or published.

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Clovis Unified Families ‘Resigned’ To Grad Ceremony Ban, Attorney Says

DON'T MISS

Hegseth Orders the Name of Gay Rights Activist Harvey Milk Scrubbed From Navy Ship

DON'T MISS

Knicks Fire Coach Tom Thibodeau After First Eastern Conference Finals Berth in 25 Years

DON'T MISS

US Judge Dismisses California’s Tariff Lawsuit, Teeing up Appeal

DON'T MISS

Young Democrats Offer Lessons for Their Leaders at Party Convention

DON'T MISS

California Prisons Have a Narcotics Problem. Now, More People Will Face Canine Searches

DON'T MISS

After Years of Undrinkable Water, Our Rural California Community Finally Has Hope

DON'T MISS

Fellow Clovis Councilmember, Public Bash Pearce Over Trans Athlete

DON'T MISS

Musk Calls Trump’s Big Beautiful Bill ‘a Disgusting Abomination’

DON'T MISS

US Tariffs Could Put Air Safety at Risk, Aerospace and Airline Industries Warn

UP NEXT

American Doctors Are Moving to Canada To Escape the Trump Administration

UP NEXT

Loretta Swit, Emmy-winner Who Played Houlihan on Pioneering TV Series ‘M.A.S.H.,’ Has Died at 87

UP NEXT

1 in 4 US Children Have Parents With Substance Use Disorder, Study Finds

UP NEXT

Dozens Sickened in Expanding Salmonella Outbreak Linked to Recalled Cucumbers

UP NEXT

Speaker Johnson Raises Campaign Money in Fresno

UP NEXT

Business Insider Cuts 21% of Workforce, Memo Shows

UP NEXT

Harvard Agrees to Relinquish Early Photos of Slaves, Ending a Long Legal Battle

UP NEXT

Silence on E. Coli Outbreak Highlights How Trump Team’s Changes Undermine Food Safety

UP NEXT

Trump Pardons Tax Cheat After Mother Attends $1 Million Dinner

UP NEXT

NPR Sues Trump Administration Over Executive Order to Cut Funding

US Judge Dismisses California’s Tariff Lawsuit, Teeing up Appeal

6 hours ago

Young Democrats Offer Lessons for Their Leaders at Party Convention

6 hours ago

California Prisons Have a Narcotics Problem. Now, More People Will Face Canine Searches

7 hours ago

After Years of Undrinkable Water, Our Rural California Community Finally Has Hope

7 hours ago

Fellow Clovis Councilmember, Public Bash Pearce Over Trans Athlete

7 hours ago

Musk Calls Trump’s Big Beautiful Bill ‘a Disgusting Abomination’

8 hours ago

US Tariffs Could Put Air Safety at Risk, Aerospace and Airline Industries Warn

8 hours ago

Trump to Sign Order Doubling Metals Tariffs, White House Says

8 hours ago

California Inmate Gets Five Years for Role in Drone Drug Smuggling Scheme

8 hours ago

Millions Invested in Land for Innovation Village. Will It Be a Fresno Game-Changer?

9 hours ago

Clovis Unified Families ‘Resigned’ To Grad Ceremony Ban, Attorney Says

Barring any last-minute about-faces by Clovis Unified officials, eight high school seniors won’t be joining their classmates at their ...

2 hours ago

2 hours ago

Clovis Unified Families ‘Resigned’ To Grad Ceremony Ban, Attorney Says

4 hours ago

Hegseth Orders the Name of Gay Rights Activist Harvey Milk Scrubbed From Navy Ship

4 hours ago

Knicks Fire Coach Tom Thibodeau After First Eastern Conference Finals Berth in 25 Years

U.S. President Donald Trump holds a chart next to U.S. Secretary of Commerce Howard Lutnick as Trump delivers remarks on tariffs in the Rose Garden at the White House in Washington, D.C., U.S., April 2, 2025. REUTERS/Carlos Barria/File Photo
6 hours ago

US Judge Dismisses California’s Tariff Lawsuit, Teeing up Appeal

6 hours ago

Young Democrats Offer Lessons for Their Leaders at Party Convention

7 hours ago

California Prisons Have a Narcotics Problem. Now, More People Will Face Canine Searches

7 hours ago

After Years of Undrinkable Water, Our Rural California Community Finally Has Hope

7 hours ago

Fellow Clovis Councilmember, Public Bash Pearce Over Trans Athlete

Help continue the work that gets you the news that matters most.

Search

Send this to a friend